NCT06582784 IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
| NCT ID | NCT06582784 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of South Carolina |
| Condition | Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 279 participants |
| Start Date | 2024-10-28 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 279 participants in total. It began in 2024-10-28 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood. Participants will be randomly assigned to either download the mobile app, "Moodivate", or not. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will not. All participants will complete electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as your experiences using Moodivate and participating in this trial. Participation in this study will take about 12 weeks, beginning today. Participation in this study may help in the treatment of future cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality. Alternative treatments include contacting your primary care provider or your oncology care team to discuss other available treatments for depressed mood.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * ILLIC (as determined during manual chart review) * Elevated depressive symptoms, defined as a score of ≥ 8 on the PHQ-9 * Current owner of an iOS- or Android-compatible smartphone * Willingness to utilize a mobile app for the treatment of depressed mood (response of "yes" on yes/no item) * Have a valid e-mail address that is checked regularly or have regular access to text messages (to access follow-up assessments) * English language fluency Exclusion Criteria: * Current suicidal ideation at study screening, defined as a response greater than or equal to 1 on item nine of the PHQ-9 * Severe cognitive impairment that precludes completion of informed consent. For the purposes of assessing eligibility, this criterion is operationalized as: * Prior diagnosis of dementia, or Major Neurocognitive Disorder indicated either via self-report or in the EHR; or * Self-report of cognitive difficulties that impair functional independence
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06582784 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06582784 currently recruiting?
Yes, NCT06582784 is actively recruiting participants. Contact the research team at dahne@musc.edu for enrollment information.
Where is the NCT06582784 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT06582784 clinical trial?
NCT06582784 is sponsored by Medical University of South Carolina. The trial plans to enroll 279 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.